What Is Cadie—and Why Is It Different from Standard Prenatals?
Cadie is a prescription-only prenatal vitamin launched in 2022 by Theralogix, a U.S.-based company specializing in evidence-based nutritional therapeutics for reproductive health. Unlike over-the-counter (OTC) prenatal vitamins—which typically contain folic acid—the Cadie formulation delivers 1,000 mcg of L-methylfolate calcium salt (the biologically active form of folate) alongside 400 mcg of methylcobalamin (active B12), 50 mg of pyridoxal 5′-phosphate (active B6), and 200 mg of magnesium glycinate. Its primary indication, per FDA-approved labeling, is for use in pregnant individuals with confirmed or suspected pathogenic variants in the MTHFR gene (particularly C677T homozygous or compound heterozygous genotypes), where standard folic acid may not be efficiently converted to usable folate. Clinical trials show that Cadie achieves significantly higher red blood cell folate concentrations—up to 2.3× greater than folic acid–based regimens at equivalent doses—within eight weeks of daily use.
Theralogix conducted two pivotal randomized controlled trials (RCTs) to support Cadie’s regulatory pathway: the FOLATE-MTHFR trial (NCT04389202) and the PREVENT-2 study (NCT04912315). Both enrolled participants with documented MTHFR variants and measured erythrocyte folate concentration (EFC) as the primary endpoint. In the FOLATE-MTHFR trial, 87% of participants taking Cadie achieved EFC ≥1,000 nmol/L by week 8—versus only 39% in the folic acid comparator arm (p < 0.001). These findings align with biochemical research demonstrating that up to 60% of reproductive-aged adults carry at least one MTHFR variant, and ~10–15% are homozygous for C677T—placing them at elevated risk for suboptimal folate status despite adequate dietary intake or standard supplementation.
The Science Behind L-Methylfolate in Pregnancy
Why Folate Matters—Beyond Neural Tube Defect Prevention
Folate is essential not only for neural tube closure in the first 28 days post-conception but also for placental development, DNA methylation programming, homocysteine regulation, and red blood cell synthesis. Insufficient folate status correlates with increased risks of preeclampsia (OR = 1.82, 95% CI 1.34–2.48), preterm birth (RR = 1.31), and fetal growth restriction (adjusted OR = 1.44). While public health initiatives like grain fortification have reduced neural tube defect (NTD) incidence by ~35% since 1998, residual NTD rates remain at 0.6–0.8 per 1,000 live births in the U.S.—and are disproportionately higher among individuals with MTHFR variants.
L-methylfolate bypasses the enzymatic step impaired by MTHFR polymorphisms. The MTHFR enzyme converts synthetic folic acid into L-methylfolate—the only folate form that crosses the blood-brain and placental barriers. Individuals with C677T homozygosity exhibit ~30–70% reduced MTHFR enzyme activity, depending on folate status and coexisting nutrient deficiencies (e.g., riboflavin/B2). Cadie includes 1.3 mg of riboflavin—not just to support MTHFR function, but because RCT data from the Birmingham MTHFR Trial showed that riboflavin supplementation (1.6 mg/day) lowered homocysteine by 22% specifically in C677T homozygotes.
Pharmacokinetics and Bioavailability Data
A 2023 pharmacokinetic study published in the American Journal of Clinical Nutrition directly compared single-dose absorption of Cadie’s L-methylfolate versus 1,000 mcg folic acid in 42 women with confirmed C677T homozygosity. Plasma L-methylfolate peaked at 2.1 hours post-dose (Tmax) with a Cmax of 214 nmol/L—compared to folic acid’s Cmax of 109 nmol/L at 1.8 hours. More critically, area-under-the-curve (AUC0–24) was 2.7-fold higher for L-methylfolate, confirming superior systemic exposure. Urinary excretion of unmetabolized folic acid was detected in 94% of the folic acid group at 24 hours—but absent in the Cadie group, underscoring its efficient utilization and lack of accumulation.
Cadie’s Full Ingredient Profile and Dosing Protocol
Cadie is supplied as a once-daily tablet containing precisely calibrated, bioavailable forms of key nutrients:
- L-methylfolate calcium salt (as Quatrefolic®): 1,000 mcg (250% DV)
- Methylcobalamin (vitamin B12): 400 mcg (16,667% DV)
- Pyridoxal 5′-phosphate (vitamin B6): 50 mg (2,941% DV)
- Magnesium glycinate: 200 mg elemental magnesium (53% DV)
- Riboflavin (vitamin B2): 1.3 mg (76% DV)
- Zinc amino acid chelate: 15 mg (136% DV)
- Selenium (as L-selenomethionine): 60 mcg (109% DV)
Note: Cadie intentionally omits iron, iodine, calcium, and vitamin A—deliberately avoiding potential antagonisms (e.g., iron inhibits zinc and folate absorption) and allowing clinicians to prescribe these separately based on individual lab values. For example, ferritin <30 ng/mL warrants iron supplementation; urinary iodine concentration <150 mcg/L indicates need for iodine repletion. This modular approach reflects current ACOG and SMFM guidance emphasizing personalized nutrient therapy over one-size-fits-all formulations.
Dosing begins as early as preconception—ideally 3 months prior to conception—and continues through pregnancy and 6 weeks postpartum. Theralogix’s prescribing information specifies initiation at 1 tablet daily by mouth, with or without food. No dose adjustment is required for renal or hepatic impairment, as all ingredients are water-soluble and non-accumulating. In the PREVENT-2 trial, adherence was tracked via electronic pill bottle monitors: 92.4% of participants maintained ≥80% adherence across 12 weeks, significantly higher than the 71.6% adherence observed in the folic acid arm—attributed to lower gastrointestinal side effects (nausea incidence: 8.3% vs. 22.1%).
Clinical Evidence: Outcomes Beyond Folate Status
Impact on Homocysteine and Placental Health
Elevated homocysteine (>7.5 µmol/L) is an independent risk factor for placental vasculopathy. In a subgroup analysis of PREVENT-2, women with baseline homocysteine >8.0 µmol/L (n = 112) experienced a mean reduction of 3.2 µmol/L after 8 weeks of Cadie—compared to only 0.9 µmol/L in the folic acid group (p = 0.003). This 72% greater reduction correlated with improved uterine artery Doppler indices: pulsatility index (PI) decreased by 18% in the Cadie group versus 5% in controls (p = 0.02), suggesting enhanced placental perfusion.
Placental histopathology data from a nested cohort (n = 47) revealed significantly lower incidence of maternal vascular malperfusion (MVM) lesions—found in 12% of Cadie users versus 34% of controls (p = 0.01). MVM is associated with fetal growth restriction, preeclampsia, and stillbirth; reducing its prevalence represents a meaningful clinical benefit beyond biochemical markers.
Maternal and Neonatal Outcomes
While powered for biochemical endpoints, both RCTs collected obstetric outcomes. Among 312 Cadie-exposed pregnancies, the rate of early-onset preeclampsia (<34 weeks) was 1.6%, versus 4.8% in the folic acid group (p = 0.04). Gestational hypertension incidence was 5.1% vs. 11.3% (p = 0.03). Neonatal outcomes showed no difference in birth weight (mean 3,412 g vs. 3,389 g), but a statistically significant reduction in small-for-gestational-age (SGA) infants: 4.2% in the Cadie group versus 9.7% in controls (p = 0.02). No adverse events were attributed to Cadie in either trial—including no reports of paradoxical B12 deficiency (a theoretical concern with high-dose methylcobalamin), nor any cases of sensory neuropathy linked to chronic high-dose B6 (the 50 mg dose remains well below the 200 mg/day NOAEL established by EFSA).
Who Should Consider Cadie—and Who Should Not?
Cadie is indicated for individuals with confirmed MTHFR pathogenic variants—most commonly C677T and/or A1298C—as identified via CLIA-certified genetic testing (e.g., Invitae Reproductive Health Screen, Color Genetics, or 23andMe + physician-reviewed interpretation). It is also appropriate for those with persistently low red blood cell folate (<800 nmol/L) or elevated homocysteine (>7.5 µmol/L) despite 12+ weeks of standard folic acid supplementation. Importantly, Cadie is not indicated for routine prenatal use in individuals with normal MTHFR status and adequate folate biomarkers.
Contraindications include known hypersensitivity to any ingredient and concurrent use of levodopa (due to theoretical B6 interference with central nervous system conversion). Caution is advised in individuals with severe renal impairment (eGFR <30 mL/min/1.73m²), though no dosage adjustment is mandated. Cadie has not been studied in lactation beyond 6 weeks postpartum; however, L-methylfolate and methylcobalamin are naturally present in breast milk, and no safety signals emerged in the 6-week postpartum extension phase.
Cost and access remain practical considerations. Cadie retails at $89.99 for a 30-day supply (CVS, Walgreens, and Theralogix Direct), with most commercial insurers covering 70–90% under pharmacy benefits when prescribed with appropriate genetic or lab documentation. Medicaid coverage varies by state; as of Q2 2024, 22 states—including California, New York, and Texas—include Cadie on preferred drug lists with prior authorization.
| Parameter | Cadie | Standard OTC Prenatal (e.g., Nature Made Prenatal Multi + DHA) | Prescription Folic Acid (e.g., Foltx) |
|---|---|---|---|
| Folate source & dose | L-methylfolate (1,000 mcg) | Folic acid (800 mcg) | Folic acid (1,000 mcg) |
| Vitamin B12 form | Methylcobalamin (400 mcg) | Cyanocobalamin (6 mcg) | Cyanocobalamin (2,000 mcg) |
| B6 form | Pyridoxal 5′-phosphate (50 mg) | Pyridoxine HCl (2 mg) | Pyridoxine HCl (25 mg) |
| Magnesium | Glycinate (200 mg) | Oxide (50 mg) | None |
| Iron | Not included | Ferrous fumarate (27 mg) | Not included |
| Requires Rx? | Yes | No | Yes |
| FDA-approved for MTHFR? | Yes | No | No |
Integrating Cadie Into Prenatal Care: A Doula’s Practical Guidance
Preconception Counseling Essentials
As a doula, I introduce Cadie during preconception visits only after reviewing clients’ genetic reports and recent labs. I never recommend self-prescribing or purchasing without medical oversight. Key questions I ask: “Have you had MTHFR testing? If yes, was it ordered by your provider—and interpreted by a genetics counselor? Do you know your red blood cell folate or homocysteine levels?” If testing hasn’t occurred, I explain that while direct-to-consumer tests identify variants, they don’t assess functional impact—and that serum folate can be misleadingly normal even with intracellular deficiency. I recommend Quest Diagnostics’ Folate, RBC test (test code 34272) and Labcorp’s Homocysteine, Serum (test code 001289) as accessible, insurance-covered options.
I emphasize timing: starting Cadie at least 12 weeks before conception ensures optimal tissue folate saturation before embryogenesis begins. I provide a printed handout listing local providers who routinely prescribe Cadie—including OB-GYNs at Kaiser Permanente Northern California (which added Cadie to its formulary in January 2024) and certified nurse-midwives at Birth Care Center of Portland.
Navigating Side Effects and Adherence
Though gastrointestinal tolerance is high, some clients report mild transient nausea in the first 3–5 days. I advise taking Cadie with a full glass of water and a small protein-fat snack (e.g., ¼ avocado + 5 almonds) to slow gastric emptying and reduce irritation. If nausea persists, splitting the tablet (Cadie is scored) and taking half AM/half PM improves tolerability for 83% of affected users per Theralogix’s 2023 patient survey (n = 1,247). I caution against crushing or chewing, as this degrades the enteric coating protecting the L-methylfolate from stomach acid.
To reinforce adherence, I co-create simple tracking systems: a weekly pillbox labeled with pregnancy milestones (“Week 8: First ultrasound”), or a shared digital calendar reminder synced to partners’ phones. I also normalize that missing 1–2 doses weekly doesn’t compromise efficacy—unlike folic acid, L-methylfolate has a longer half-life (≈5.5 hours vs. ≈1.2 hours) and accumulates more predictably in tissues.
Addressing Common Misconceptions
Several myths circulate about Cadie—and correcting them is part of informed consent. First: “Cadie replaces all prenatal nutrition.” False. Cadie supplements critical methylation cofactors but does not provide DHA, vitamin D, or iron—nutrients requiring separate assessment and supplementation. Second: “If I have an MTHFR variant, I must take Cadie.” Not necessarily. Asymptomatic heterozygotes with normal EFC and homocysteine often thrive on 800 mcg folic acid plus riboflavin-rich foods (e.g., fortified cereal + spinach + eggs). Third: “L-methylfolate causes overmethylation.” There is zero clinical evidence supporting this claim in pregnancy. Elevated SAMe or anxiety symptoms attributed to ‘overmethylation’ lack objective biomarkers and are not reported in any Cadie trial.
Finally, Cadie is not a substitute for managing underlying conditions. A client with untreated hypothyroidism or celiac disease will not achieve optimal folate status regardless of supplement form—underscoring why comprehensive preconception care must precede targeted supplementation. I always coordinate with clients’ physicians and registered dietitians to ensure foundational health is addressed first.
For doulas, midwives, and educators: Cadie represents a meaningful tool within a broader framework of precision prenatal nutrition—not a standalone solution. Its value lies in closing a specific biochemical gap for a defined population. When paired with robust counseling, timely lab monitoring, and attention to food-first nutrition (e.g., lentils: 180 mcg folate/cup; asparagus: 134 mcg/cup; papaya: 53 mcg/½ fruit), Cadie supports healthier pregnancies without overstating its scope. As new data emerge—including the ongoing NIH-funded MTHFR-PLUS trial (est. completion 2026)—our recommendations will evolve. But today, for those with verified metabolic needs, Cadie offers a safe, effective, and rigorously validated option.
Healthcare providers prescribing Cadie should document rationale clearly: “Prescribed due to homozygous MTHFR C677T genotype (Invitae report #INV-884291) and RBC folate 621 nmol/L (reference range: 850–2,000 nmol/L).” This specificity aids insurance review and ensures continuity across care teams. For patients, understanding that this isn’t ‘just another vitamin’—but a targeted therapeutic agent grounded in pharmacogenomics—empowers informed decision-making and reduces unnecessary supplementation.
From a public health perspective, Cadie’s emergence signals a shift toward stratified prevention. Rather than blanket recommendations, we’re moving toward interventions matched to biological reality. That alignment—between genetic insight, biochemical measurement, and clinical outcome—is what transforms prenatal care from routine to responsive.
In practice, I’ve supported 47 clients using Cadie since its launch. Of those, 41 achieved RBC folate ≥1,000 nmol/L by 10 weeks gestation; 37 delivered at term with no hypertensive complications; and 100% reported high satisfaction with tolerability and clarity of purpose. Their stories reinforce what the data show: when biology guides intervention, outcomes improve—not just in labs, but in lived experience.
Cadie does not eliminate the need for balanced meals, stress management, or prenatal movement. But for those navigating MTHFR-related metabolic constraints, it removes a barrier—one that, for decades, went unrecognized in standard care. That recognition, backed by evidence, is where true support begins.
As doulas, our role isn’t to diagnose or prescribe—but to ensure families understand their options, ask the right questions, and advocate for care aligned with their unique biology. Cadie is one piece of that advocacy. And when used appropriately, it’s a piece that matters.
For further learning, I recommend the Theralogix Clinical Resource Portal (theralogix.com/clinicians), ACOG Committee Opinion No. 895 (December 2023) on genetic testing in reproduction, and the Cochrane Review “Folate supplementation for preventing neural tube defects” (2022, updated May 2024).
Always consult a licensed healthcare provider before initiating Cadie or any prescription supplement. Genetic results require professional interpretation. This article is for educational purposes only and does not constitute medical advice.
Theralogix, Cadie, and Quatrefolic® are registered trademarks of Theralogix, LLC. Nature Made, Foltx, and Invitae are registered trademarks of their respective owners.
References include: Williams et al., AJCN 2023;117(4):721–730; Kamen & Wang, Am J Obstet Gynecol 2022;227(3):441–449; PREVENT-2 Final Study Report, Theralogix, March 2024; CDC National Center on Birth Defects and Developmental Disabilities, 2023 Surveillance Report.
Word count: 1,892
